Internal Medicine
Audio Summaries

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

The study aimed to evaluate the efficacy of adding the tyrosine kinase inhibitor Quizartinib to intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), regardless of FLT3 mutation status. While Quizartinib did not improve overall survival for the entire cohort, it significantly enhanced survival in FLT3-mutated patients, particularly those receiving a shorter duration of treatment. The findings suggest that Quizartinib may be beneficial for specific subgroups, highlighting the importance of genetic profiling in treatment strategies.

Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips

This study investigates the relationship between central acetabular osteophytes (CAOs) and microinstability in hips with borderline developmental dysplasia (BDDH). The authors found that BDDH hips with CAOs exhibited higher rates of microinstability, ligamentum teres tears, and increased combined anteversion compared to those without CAOs, suggesting that CAOs may serve as a radiographic marker for instability and early osteoarthritis in this patient population.

NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab

The authors investigate the role of the NG2-ITGA4 signaling axis in the aggressiveness of KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL), a subtype associated with poor prognosis and high relapse rates. They demonstrate that NG2 promotes cell proliferation and migration through Rho GTPase activity in an ITGA4-dependent manner, and show that targeting ITGA4 with natalizumab can delay leukemia progression and enhance chemotherapy efficacy in patient-derived models. This study highlights a potential therapeutic strategy for improving outcomes in KMT2A-r B-ALL patients.

Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate

The authors investigate how mRNA isoform regulation influences the fate decisions of hematopoietic stem cells (HSCs) during their transition from quiescence to lineage commitment. They identify the splicing regulator Sf1 as a critical component of a translationally controlled splicing program that modulates HSC differentiation and DNA damage response through alternative splicing. This study highlights the intricate relationship between translational regulation, splicing, and HSC fate determination.

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

This study investigates the role of galectin-1 (Gal-1) in driving monocyte hyperinflammation in myeloproliferative neoplasms (MPNs). The authors demonstrate that elevated Gal-1 levels in MPN monocytes enhance inflammatory cytokine production through TLR4 and NF-κB signaling pathways, suggesting that targeting Gal-1 could represent a novel therapeutic strategy for managing MPN-related inflammation.

Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals

The authors investigate the ethical implications of "slow codes" in U.S. hospitals, where clinicians perform resuscitation efforts without full commitment, often in response to patient or family requests despite the futility of such interventions. Their systematic review of 34 studies reveals a significant divide among physicians regarding the permissibility of slow codes, with most ethics literature deeming them impermissible due to concerns about deception, patient autonomy, and moral distress. The findings underscore the need for improved communication and ethical guidance in navigating end-of-life care decisions.

Trends in Public Opinion About US Illicit Drug Policy: Results From the 2000 to 2025 Gallup Survey

This study investigates American perceptions of progress in illicit drug policy and the severity of the drug problem from 2000 to 2025, utilizing data from the Gallup Poll Social Survey. The findings reveal that less than half of Americans consistently perceive progress against illicit drugs, with significant partisan differences influencing these perceptions, particularly in the context of political leadership. The authors highlight that increasing political polarization may hinder the development of a unified national drug control strategy.

Medicaid Prior Authorization and Discontinuation of Buprenorphine

The authors investigate how Medicaid's utilization management policies, specifically prior authorization (PA), affect the duration of buprenorphine treatment episodes for opioid use disorder. Their analysis of national prescription claims data reveals that buprenorphine discontinuation rates are high across all Medicaid plans, with a notable decline in treatment continuation observed within the first three months, particularly among managed care organization (MCO) plans with PA. The findings suggest a need for further research into additional insurer policies that may impact treatment adherence.

Assessing early effects of Australia's Social Media Minimum Age Act on adolescents' social media use: observational study

The study aimed to assess the early effects of Australia's Social Media Minimum Age Act 2024, which set a minimum age of 16 for social media accounts, on adolescents' social media use. Findings indicated that while many adolescents under 16 continued to use social media, with some reporting attempts to circumvent age verification, there was no significant reduction in overall social media use among this group. The results suggest that the Act has not yet achieved its intended goal of delaying access to social media for younger adolescents.

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

This study aimed to evaluate the safety, tolerability, and preliminary efficacy of AC01, an oral ghrelin receptor agonist, in patients with heart failure with reduced ejection fraction (HFrEF). The results indicated that AC01 was generally safe and well tolerated over 28 days, with no major adverse events reported, suggesting potential for further investigation in larger trials.